Gosset research
Reports: Immunology
Gosset reports matching these filters, newest first.
8 items Clear filters
Report
HCXT-2001: oral IL-23R inhibition
Inside the oral IL-23R program behind Gilead’s announced acquisition agreement: mechanism, clinical evidence and competition.
Worked example
TL1A competitive landscape
TL1A pipeline data, market dynamics, ownership charts and a downloadable spreadsheet.
Research article
Tegoprubart: a CNI-free bet on tolerability in kidney transplant
Eledon’s anti-CD40L antibody missed its Phase 2 efficacy endpoint yet separated sharply from tacrolimus on safety.
- Undated
Landscape
TL1A research landscape
TL1A biology in inflammatory bowel disease, the Merck, Roche and Sanofi-Teva Phase 3 race, clinical evidence, patents and deals.
- Undated
Landscape
TSLP research landscape
How tezepelumab set the benchmark in severe asthma and nasal polyps, and the programs testing new dosing, delivery and targets.
- External sample
Landscape · External · Google Sheets
Competitive landscaping: Anti-TL1A antibodies in inflammatory bowel disease (opens Google Sheets on Google Drive)
Every drug targeting a given target or modality, with detailed development status.
- External sample
Report · External · Google Sheets
Head-to-head results: IL-13 vs IL-4Rα biologics in atopic dermatitis (EASI-75, IGA 0/1) (opens Google Sheets on Google Drive)
Side-by-side comparison of trial outcomes for a drug class or indication. Covers safety, efficacy, patient population, and trial design.